Andrew Brohl, MD
Enriched profileMedical Oncologist, Sarcoma Program; Associate Member, Moffitt Cancer Center · Moffitt Cancer Center
Andrew Brohl is Medical Oncologist, Sarcoma Program; Associate Member, Moffitt Cancer Center at Moffitt Cancer Center. OpenAlex indexes 331 publications with 6,787 citations (h-index 34); ClinicalTrials.gov lists 8 registered studies with this person as an investigator.
Data verified 17 Oct 2026
Overview
Updated 18 Oct 2026
Andrew Brohl, M.D., is Medical Oncologist, Sarcoma Program at Moffitt Cancer Center. The public record shows 331 publications with 6,787 citations (h-index 34), centered on Cancer Immunotherapy and Biomarkers, Sarcoma Diagnosis and Treatment, Cancer Genomics and Diagnostics. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 6 companies, 1 NIH-funded awards (2021–2023).
- Most recent indexed publication: 2026 · JCO oncology practice
- Top research focus: Cancer Immunotherapy and Biomarkers
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 6 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 19 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 69.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Industry payments
Updated 18 Oct 2026
6 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Deciphera Pharmaceuticals Inc.Program year20251 payment
- Merck Sharp & Dohme LLCProgram year20251 payment
- Ethicon US, LLCProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
49.5%Kinase inhibitor49.5%Imatinib Mesylate38%Pazopanib Hcl38%Gleevec25%Part D<11 patientsHormonal (systemic)
20.6%l-Thyroxine20.6%Levothyroxine Sodium100%Part D<11 patientsDermatology
15.5%Corticosteroid15.5%Methylprednisolone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
1 NIH research award on record, funded 2021–2023 per NIH RePORTER. The latest:
- Role of the Chromosome 19 MicroRNA Cluster in Liver Cancers
H. Lee Moffitt Cancer Ctr & Res Inst
FY2023$248,813K08CA255933 - Role of the Chromosome 19 MicroRNA Cluster in Liver Cancers
H. Lee Moffitt Cancer Ctr & Res Inst
FY2022$248,813K08CA255933 - Role of the Chromosome 19 MicroRNA Cluster in Liver Cancers
H. Lee Moffitt Cancer Ctr & Res Inst
FY2021$248,813K08CA255933
Congress activity
Updated 18 Oct 2026
64 congress contributions (2010–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- A phase II study of neoadjuvant ipilimumab-nivolumab-relatlimab (INR) combination immunotherapy in high-risk resectable melanoma.
ASCO Annual Meeting
ASCO2026Co-author - A phase II trial of olaparib in combination with pembrolizumab in metastatic uveal melanoma.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Evaluation of the Feasibility and Safety of Ifosfamide-Based Chemotherapy Regimens for Sarcomas in the Outpatient Setting.
JCO oncology practice
Article2026 - Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial.
Nature cancer
Clinical Trial2026 - Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial.
Journal for immunotherapy of cancer
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue SarcomasArticle1,067 citations2017
- 02
- 03The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 MutationArticle439 citations2014
- 04
- 05
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/andrew-brohl-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
University of Miami Leonard M. Miller School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →moffitt.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →moffitt.org ↗
- Fellowship in Hematology and Oncology
National Cancer Institute
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →moffitt.org ↗ - Internal Medicine Residency
Georgetown University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →moffitt.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Ignacio Wistuba, MD
Moffitt Cancer Center
Christine Chung, MD
Moffitt Cancer Center
Jonathan Strosberg, MD
Moffitt Cancer Center
Hatem Soliman, MD
Moffitt Cancer Center
George Demetri, MD
Dana-Farber Cancer Institute; Professor of Medicine
Richard Gorlick, MD
The University of Texas MD Anderson Cancer Center
William Tap, MD
Memorial Sloan Kettering Cancer Center
Scott Schuetze, MD
University of Michigan Medical School